Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06272058 · ClinicalTrials.gov registry record · Phase 1
A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT06272058 is a Phase 1 study that was terminated before completion, run by Boehringer Ingelheim. The registered enrollment target is 4 participants.
The verdict
NCT06272058, a Phase 1 study, was terminated before completion, sponsored by Boehringer Ingelheim.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study is open to people with and without severe liver problems. People can join the study if they are 18 to 80 years of age and have a body mass index (BMI) between 18.5 and 42 kg/m2. Avenciguat (BI 685509) is a medicine that is being developed to treat high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether having liver problems influences how Avenciguat (BI 685509) is taken up in the body. All participants take Avenciguat (BI 685509) once as a tablet. Participants are in the study for slightly longer than 1 month. Following the screening period of about 4 weeks, they stay at the study site for 4 nights. Afterwards, there are 2 visits to the study site. The site staff measures the amount of Avenciguat (BI 685509) in the blood. The doctors also regularly check participants' health and take note of any unwanted effects.
Interventions
- DRUG Avenciguat (BI 685509)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-05-03 |
| Est. Completion | 2024-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06272058
The ClinicalTrials.gov registry entry for NCT06272058 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Avenciguat (BI 685509) is the first listed.
NCT06272058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06272058 about?
NCT06272058 is a clinical study titled "A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems". This study is open to people with and without severe liver problems. People can join the study if they are 18 to 80 years of age and have a body mass index (BMI) between 18.5 and 42 kg/m2. Avenciguat (BI 685509) is a medicine that is being developed to treat high blood pressure in the portal vein (...
What is the current status of trial NCT06272058?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2024-05-03. Estimated completion is 2024-07-02.
What interventions are being tested in trial NCT06272058?
The interventions under investigation include: Avenciguat (BI 685509) (DRUG).
Who is sponsoring clinical trial NCT06272058?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.